Source link : https://www.newshealth.biz/health-news/high-uptake-of-rsvpref-and-nirsevimab-among-infants/
TOPLINE: Nearly three fourths of infants born during the 2023-2024 respiratory syncytial virus (RSV) season received protection with either nirsevimab or exposure to maternal RSVpreF, with maternal RSVpreF exposure being higher among infants of older mothers, while nirsevimab was predominantly administered to infants of younger mothers. METHODOLOGY: In 2023, two new measures to protect infants […]
Author : News Health
Publish date : 2025-02-25 05:27:02
Copyright for syndicated content belongs to the linked Source.
inHealth